Answers are grounded in this paper and cite their sources.
BACKGROUND Gastric cardia cancer is a distinct clinicopathological entity with an increasing global incidence. Because of its location at the esophagogastric junction and complex submucosal architecture, early gastric cardia neoplasms pose significant challenges for accurate endoscopic diagnosis and depth assessment. These difficulties may lead to pathological underestimation and high rates of noncurative resection (NCR) after endoscopic submucosal dissection (ESD). Although additional surgery is generally recommended for NCR, this strategy may lead to overtreatment in selected low-risk patients. Therefore, evaluating the diagnostic performance of endoscopic modalities and exploring individualized management strategies after ESD are important clinically. AIM To evaluate ESD efficacy and safety for early gastric cardia neoplasms and explore individualized management for patients undergoing NCR. METHODS We retrospectively analyzed 155 patients with 163 early gastric cardia mucosal lesions treated by ESD between March 2014 and June 2025. Diagnostic accuracy of white-light endoscopy, magnifying endoscopy with narrow-band imaging, and endoscopic ultrasonography was evaluated using postoperative pathology as the reference standard. ESD outcomes, management of NCR, and long-term survival were assessed. Logistic regression identified factors associated with NCR, and survival was analyzed using Kaplan-Meier and Cox models. RESULTS Most lesions were classified as E = G type (Nishi classification) and located on the posterior wall of the cardia. White-light endoscopy showed a diagnostic accuracy of 70.6% (κ = 0.21), compared with 84.3% (κ = 0.54) for magnifying endoscopy with narrow-band imaging. Endoscopic ultrasonography demonstrated an accuracy of 69.5% (κ = 0.12) for assessing invasion depth. All lesions were removed en bloc ; histologically complete resection was achieved in 82.8% of cases, and 73.0% met the e-Cura criteria for curative resection. Complications were rare (bleeding 1.8%). The 5-year overall survival and disease-free survival rates were 97.0% and 94.5%, respectively. Of the 44 patients with NCR (27.0%), 7 underwent additional surgery (with no residual tumor or nodal metastasis found) and 37 opted for surveillance. The 5-year disease-free survival was 85.7% in the surgery group and 93.5% in the surveillance group. CONCLUSION ESD is effective for early gastric cardia neoplasms. Individualized surveillance for low-risk NCR patients helps reduce overtreatment and improve clinical prognosis.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: